Ken Song's post-RayzeBio venture pulled together two licensing deals, an M&A transaction and three financings totaling $370M

Candid's $370 million debut heats up the race to turn B cell-targeting bispecific T cell engagers into autoimmune therapies, and highlights how this emerging space positions China's next-gen antibody pipelines as a fountain of derisked assets.

Founder and CEO Ken Song told BioCentury the oncology-to-autoimmunity pivot for bispecific T cell engagers (TCEs) is emblematic of the type of opportunity to "get into something at the early part of the curve" he has sought throughout his career. ...